Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 to 75				Other				KMU-IRB00003151 VGHKS95-CT3-11, NCT00656968

Last Modified: 6/6/2008 First Published: 9/16/2005


2.		Phase III Randomized Study of Induction Therapy Comprising Two Different Doses of High-Dose Melphalan and Amifostine Followed by Single or Double Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Maintenance Therapy Comprising Clarithromycin, Thalidomide, and Dexamethasone in Patients With Stage II or III Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				NCI, Pharmaceutical / Industry				FHCRC-2004.00 MEDIMMUNE-FHCRC-2004.00, NCT00217438


3.		Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 75				Other				HELYX Study NCT00154440

Last Modified: 12/21/2007 First Published: 9/9/2005


4.		Phase II Study of Maintenance Therapy Comprising Thalidomide, Dexamethasone, and Clarithromycin in Patients With Multiple Myeloma Who Have Undergone Prior Autologous or Syngeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Not specified				NCI, Pharmaceutical / Industry				FHCRC-1767.00 CELGENE-FHCRC-1767.00, NCT00182663

Last Modified: 5/15/2007 First Published: 3/2/2007


5.		Phase II Study of Maintenance Therapy Comprising Lenalidomide, Dexamethasone, and Clarithromycin in Patients Who Have Undergone Autologous or Syngeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				FHCRC-2135.00 NCT00445692


6.		Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				07-038 NCT00461084


7.		Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Other				0707009285 RV-MM-PI-238, NCT00538733


8.		Prospective Study of First-Line Antibiotic Therapy for Early-Stage Gastric MALT Lymphoma for Treatment Outcome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Biomarker/Laboratory analysis, Treatment				Active				No age specified				Other				T3206 NCT00327132

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute